



**pan-Canadian Oncology Drug Review
Stakeholder Feedback on a pCODR Expert
Review Committee Initial Recommendation
(Patient Advocacy Group)**

Niraparib (Zejula) for first line Ovarian Cancer

Ovarian Cancer Canada

April 29, 2021

3 Feedback on pERC Initial Recommendation

Name of the Drug and Indication(s):	Niraparib (Zejula) for first line Ovarian Cancer
Eligible Stakeholder Role	Patient advocacy group
Organization Providing Feedback	Ovarian Cancer Canada

* CADTH may contact this person if comments require clarification. Contact information will not be included in any public posting of this document by CADTH.

3.1 Comments on the Initial Recommendation

a) Please indicate if the stakeholder agrees, agrees in part, or disagrees with the initial recommendation:

Agrees Agrees in part Disagrees

Niraparib has the potential to extend the time between chemotherapy treatments and therefore potentially prolong the use of platinum-based chemotherapy. This gives women and their families - regardless of whether they have a *BRCA1/2* mutation - more opportunity to focus on emotional and physical recovery. There are very few treatment options for those with ovarian cancer, particularly those without a *BRCA* mutation, so given niraparib has proven clinical benefit for ovarian cancer patients we support its approval.

b) Please provide editorial feedback on the initial recommendation to aid in clarity. Is the initial recommendation or are the components of the recommendation (e.g., clinical and economic evidence) clearly worded? Is the intent clear? Are the reasons clear?

Page Number	Section Title	Paragraph, Line Number	Comments and Suggested Changes to Improve Clarity

3.2 Comments Related to Eligible Stakeholder Provided Information

Notwithstanding the feedback provided in part a) above, please indicate if the stakeholder would support this initial recommendation proceeding to final recommendation (“early conversion”), which would occur two business days after the end of the feedback deadline date.

<input checked="" type="checkbox"/> Support conversion to final recommendation. Recommendation does not require reconsideration by pERC.	<input type="checkbox"/> Do not support conversion to final recommendation. Recommendation should be reconsidered by pERC.
---	---

If the eligible stakeholder does not support conversion to a final recommendation, please provide feedback on any issues not adequately addressed in the initial recommendation based on any information provided by the stakeholder during the review.

Please note that new evidence will be not considered at this part of the review process, however, it may be eligible for a resubmission.

Additionally, if the eligible stakeholder supports early conversion to a final recommendation; however, the stakeholder has included substantive comments that requires further interpretation of the evidence, the criteria for early conversion will be deemed to have not been met and the initial recommendation will be returned to pERC for further deliberation and reconsideration at the next possible pERC meeting.

Page Number	Section Title	Paragraph, Line Number	Comments related to Stakeholder Information